Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses recommendations for Vitamin D3 supplements for hair health. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

The user shared progress pictures showing hair thickening after 3 months of using a topical treatment of 0.3/6% finasteride/minoxidil. They also maintained their hair health with 1% Nizoral twice a week and dermastamping every 1.5-2 weeks.

The user recommends a thickening clay as a great pre-styling product for hair volume and texture, despite its poor hold. They also mention using finasteride and express skepticism about the effectiveness of a shampoo containing saw palmetto and caffeine.

Fluorescent lighting makes hair look thinner, causing concern about appearance. Some users consider treatments like DUT, while others share experiences of hair looking better in different lighting or conditions.

Hair loss discussion focused on 2% Fluridil's peak efficacy at 3 months and 7% Fluridil group buy results, including shedding decrease, side effects, and regrowth.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

A user shared 3-month hair regrowth results using a combination of oral Dutasteride, daily Minoxidil, RU58841, micro-needling, Keto shampoo, scalp massages, and supplements. Positive progress was noted, and encouragement to continue was given.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.

HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

Hair cloning trials by Stempsen Therapeutics and Hairclone have no updates, and it may take at least 15 years for hair cloning to be available. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.

Comparing two upcoming topical hair loss treatments, Fluridil and Breezula, to determine which is most effective for treating hair loss, taking into consideration factors such as price, side effects, potential for hair growth, convenience of application, smell, greasiness, and styling after use.

The user experienced side effects with both oral and topical finasteride and is considering making their own hair loss treatment using CB-03-01 (Breezula) mixed with minoxidil due to fewer reported side effects. They plan to use a lower concentration than what was used in trials.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.

The conversation is about someone's 3-month hair regrowth progress using 5mg oral minoxidil and 0.5mg dutasteride daily, with visible improvement noted.

The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.

The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.

A user shared a 3-month progress update on using minoxidil and finasteride for hair regrowth, noting thicker hair. Replies included congratulations and advice on consistent lighting for photos.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A 23-year-old noticed crown thinning and started using 1.25mg finasteride, biotin supplements, biotin/collagen shampoo, and 1% nizoral shampoo. After 3 months, they reported improvement and side effects that subsided after 2 months.